Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.

After 96 weeks, switching from PI/r to dolutegravir in PWH with high cardiovascular risk led to significant changes in several biomarkers associated with cardiovascular disease. Although most changes were favourable, adiponectin reduction was not. There were non-significant changes in CIMT progression.